Results 171 to 180 of about 47,232 (218)

What Is Your Diagnosis? Multiple Subcutaneous Lumps in a Horse

Veterinary Clinical Pathology, EarlyView.
Federica Meistro, Maria Virginia Ralletti, Riccardo Rinnovati, Alessandro Spadari, Maria Morini   +4 more
wiley   +1 more source

Updates on intratumoral therapies in melanoma

Cancer, Volume 132, Issue 13, 1 July 2026.
Abstract Intratumoral therapies provide an opportunity for novel strategies in the management of advanced melanoma. These approaches deliver concentrated doses of therapeutic immune agents directly into individual tumor(s), achieving local tumor control and induction of systemic antitumor immune responses while minimizing the risk of immune‐related ...
Vincent T. Ma, Alyssa K. Steimle, Janmesh D. Patel, Caroline Burkey, Justin C. Moser, Asad Javed, Hibba tul Rehman, Mustafa Ege Seker, Alexander Birbrair, Orhan S. Ozkan, Mark R. Albertini, Yana G. Najjar, Rajan P. Kulkarni   +12 more
wiley   +1 more source

Lymphomatoid papulosis type D with γδ phenotype evolving from pityriasis lichenoides in a pediatric patient. [PDF]

JAAD Case Rep
Watchirakaeyoon P, Sitthinamsuwan P, Wisuthsarewong W, Chairatchaneeboon M.   +3 more
europepmc   +1 more source

Guidelines or Other Guidance Documents for Rare Diseases in the Netherlands: When and Where to Invest (Effort, Time and Money)?

Clinical and Public Health Guidelines, Volume 3, Issue 3, July 2026.
ABSTRACT Introduction Developing Clinical Practice Guidelines (CPGs) is resource‐intensive, making it essential to prioritise those CPG projects that are most needed. One of the rules pertains to prevalence, which excludes virtually all guideline development for rare diseases. Still, guidance is needed for their management.
Iméze J. Hieltjes, Charlotte M. W. Gaasterland, Marieke Hermsen, Anne Marie van Wermeskerken, Ilse van Herk, Johanna H. van der Lee   +5 more
wiley   +1 more source

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies. [PDF]

Blood Cancer J
Umyarova E, Sharp J, Pei C, Pellegrino W, Zhao Q, Denlinger N, Voorhees T, De Lima M, Epperla N.   +8 more
europepmc   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, Volume 159, Issue 1, Page 11-29, 1 July 2026.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source

Revisiting the Origins of Cutaneous T-Cell Lymphoma: A Progenitor-Based Model. [PDF]

Cancers (Basel)
Zhang Y, Sokol L.
europepmc   +1 more source

The Risk of Lymphoma in Inflammatory Bowel Disease and its Association With Immunosuppression: A Systematic Review and Meta‐Analysis

JCC Plus, Volume 1, Issue 4, July 2026.
ABSTRACT Background and Aims There is a recognised association between inflammatory bowel disease (IBD) and lymphoma. However, the magnitude of lymphoma risk and impact of immunosuppression remain uncertain. Existing syntheses are limited by pooling of Crohn's disease (CD) and ulcerative colitis (UC) risk, conflation of disease‐ and treatment ...
Robert D. Lees, Alexandra Hickey, Ryan P. W. Kenny, Christopher A. Lamb, Laura M. Woods, R. Ally Speight   +5 more
wiley   +1 more source

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. Report of three cases. [PDF]

An Bras Dermatol
Vargas-Mora P, Vera-Santis G, Godoy-Sánchez D, Yagnam-Díaz M, Luzoro-Vial A, Baksai-Elespuru K.   +5 more
europepmc   +1 more source

A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma

MedComm, Volume 7, Issue 7, July 2026.
This phase II trial suggests the potential of perioperative camrelizumab plus neoadjuvant chemotherapy in patients with resectable stage IIB‐IIIB lung squamous cell carcinoma. The major pathological response rate (primary endpoint) was 60.0%, and the pathological complete response (pCR) rate was 44.4%.
Mingming Hu, Shuku Liu, Yi Han, Feng Wang, Yang Liu, Baohua Lu, Hongxia Li, Yuan Gao, Ying Wang, Wei Yang, Kang Shi, Bo Xiao, Qunhui Wang, Juan Du, Haifeng Lin, Xiaomi Li, Chong Wang, Tongmei Zhang   +17 more
wiley   +1 more source